Traitomic Raises €20M for Customer Trait Development
A breeder bringing its best plant variety to Traitomic arrives with something worth preserving. The Copenhagen biotechnology company develops targeted improvements in plants and microorganisms, working in customers' own biological material where applicable. That makes the starting point commercially important: the customer wants a useful new characteristic while retaining the qualities that already make the organism valuable.
Traitomic's €20M Series A, announced on November 17, 2026, finances a larger role in that development process. Sofinnova Partners led the round, with EIFO, The Footprint Firm, Nordic Foodtech VC, PSV Hafnium and SVG Ventures participating. The Carlsberg Research Laboratory spinout plans international expansion and closer work with customers, putting scientific delivery and the customer relationship inside the same investment story.
Traitomic's financing follows a scientific inheritance
Co-founders Gustav Hambraeus, Toni Wendt and Jan Gottlieb bring different parts of that assignment together. Funding-day investor EIFO identifies Hambraeus as CEO, Wendt as CTO and Gottlieb as CCO; Traitomic's own leadership page lists the corresponding managing, technology and commercial leadership functions. The company is headquartered in Denmark, with an Australian subsidiary and a commercial presence in the United States.
Carlsberg established Traitomic to commercialize research beyond the brewery. ABG Sundal Collier, the transaction's exclusive financial advisor, confirms the amount, Series A designation and investor syndicate. The financing is described as Traitomic's first external investment since its spinout. Public announcements do not disclose a valuation or establish how much Carlsberg invested in the underlying work over its lifetime.
That history changes how the round should be read. Outside investors are joining a business carrying laboratory experience and existing customer projects, while supporting the work of serving a wider market. The economic task is to make the scientific capability usable across distinct customer needs without treating every organism or development brief as interchangeable. A food ingredient developer and a seed business can arrive with very different definitions of a successful project.
FIND-IT connects a genetic target to biological material
Traitomic's development process begins with the customer's objectives and biological starting point. Its FIND-IT technology combines controlled genetic variation with targeted screening, allowing the team to identify and isolate material carrying a desired genetic change. Assessment then checks the material against the agreed objective, including whether the intended trait has been achieved.
The scientific method deserves precise language. Original research published in New Biotechnology describes a yeast application combining random mutagenesis, droplet digital PCR screening and isolation of selected mutant strains. Calling the approach non-GM or non-GE should not be read as saying genetic variation never occurs. The distinction concerns the method used to generate and identify useful changes, and the paper supports a specific application rather than proving every commercial outcome.
Where applicable, Traitomic develops a trait directly in a customer's relevant material. A developer may already know a variety or production strain well and want to improve a defined characteristic. Preserving that starting point makes the screening result part of an existing development program. Further testing, product decisions and commercialization still have to follow the scientific handoff.
A results-based offer makes the project brief consequential
Traitomic presents its commercial approach under the phrase “No trait, no cost.” Its public offering describes flexible, results-driven work ranging from individual projects to longer partnerships. Pricing and detailed contract terms are not public, so the phrase should be understood as the company's commercial positioning rather than a complete account of how every engagement is billed.
The offer gives project definition unusual weight. Before anybody evaluates a result, the parties need an objective they can recognize in the biological material: a change in quality, resilience or production performance. A commercially useful brief connects the desired characteristic with the customer's existing capabilities and timelines. Finding a genetic change is one part of that relationship; agreeing what the change must accomplish is another.
The funding supports more involvement across that process. In a direct interview with AgFunderNews, Hambraeus described plans to expand local teams in the US and Australia and work more closely with customers through development. That draws scientific capacity toward customer-specific work. As an operating implication, a broader service also means more decisions about which projects to support and how far the team should accompany each one.
Delivered traits leave a commercial journey still moving
Traitomic reports 116 traits delivered to 47 customers across 32 organisms. Those figures describe a development footprint across plant breeding, food and industrial biotechnology; they do not identify 116 consumer products already launched. In a Tech Funding News interview, Hambraeus discussed roughly 100 traits in pre-commercial assessment with customers. The same interview explains that Carlsberg retains FIND-IT's intellectual property and Traitomic holds an exclusive licence for uses outside brewing.
The distinction between development and adoption matters across agricultural biotechnology. DevCuration's coverage of BioConsortia's microbial seed treatments follows capital into manufacturing, regulatory work and commercial launches. Its reporting on IMIO's crop-residue biologicals follows another Sofinnova-backed business into expanded production. These are different technologies and commercial models, with their own routes from biological performance to customer use.
For Traitomic, a longer customer relationship keeps the development team close to the point where a trait becomes useful. The assessment has to return to the objective that brought the customer into the laboratory in the first place. Hambraeus, Wendt and Gottlieb now have outside capital behind more of that work, with each delivery carrying a customer's next breeding or production decision along with it.
Agricultural Biotechnology funding, last 30 days
DevCuration's funding database tracked 2 Agricultural Biotechnology rounds totaling $12.1M in disclosed capital over the past 30 days. Recent deals we covered:
- Catalera Gets $98.4K for Canadian Seed-Treatment TrialsGrant · $98.4K · Oct 23
- IMIO Raises $12M Seed to Expand Crop Residue BiologicalsSeed · $12M · Oct 20
Frequently Asked Questions
What does Traitomic deliver to a plant breeder or biotech customer?
Traitomic identifies and isolates biological material carrying a desired genetic change, then assesses whether the intended trait has been achieved. Where applicable, it works directly in the customer’s own material, which can then enter further development and commercialization.
How does FIND-IT differ from gene editing?
Traitomic describes FIND-IT as combining controlled genetic variation with targeted screening. Original yeast research used conventional random mutagenesis and droplet digital PCR screening to isolate variants, rather than targeted gene editing.
Do 116 delivered traits mean 116 products have reached consumers?
No. The company-reported figure describes traits delivered to customers, while downstream assessment and commercialization are separate milestones. The number of resulting market launches has not been publicly established in the verified sources.
What customer work will the Series A support?
The €20M financing supports international expansion and a broader role from defining a biological or commercial challenge through development and assessment. Gustav Hambraeus identified the US and Australia as priorities for expanding local teams.
What is known about Traitomic’s results-based commercial model?
Traitomic markets a flexible, results-driven approach under “No trait, no cost.” Public sources do not disclose pricing or full contract terms, so customers would need to establish the scope, success criteria and commercial terms for their specific project.
Where the Money Moved
The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.
Subscribe to Where the Money Moved